Mucopolysaccharidoses (MPS Disease): Symptoms, Causes & Treatment

When it comes to the discussion of rare diseases, there are many conditions that hide in plain sight; their symptoms may mimic common issues, with their causes hidden deep within our genes. Over time, they quietly affect how the body grows, heals, and functions. One such group of disorders is Mucopolysaccharidoses, or MPS. 

Though rare, MPS involves a number of systems, including skeletal structure, facial features, vision, hearing, and even heart health. Understanding its development, symptoms that may arise, and available treatment can help ensure early intervention and a better quality of life for those living with it.

What is MPS Disease?

Mucopolysaccharidoses, or MPS, are a group of inherited metabolic disorders that affect the body’s ability to break down glycosaminoglycans, or GAGs. These complex sugars are essential for building and maintaining connective tissues such as bones, cartilage, skin, and organs. Normally, the body uses specific enzymes to recycle GAGs once they have completed their role. In individuals with MPS, one or more of these enzymes is missing or not functioning correctly due to a genetic mutation.

When GAGs are not broken down, they accumulate inside lysosomes, the part of the cell responsible for managing waste. This buildup slowly disrupts normal cell activity and affects multiple organs. Over time, tissues enlarge, lose function, and lead to noticeable physical changes such as joint stiffness, abnormal bone growth, coarse facial features, and enlargement of organs. Some forms of MPS also impact the brain and nervous system, which can cause developmental or cognitive difficulties.

In simple terms, MPS occurs when the body’s natural recycling of certain sugars is interrupted. This turns a routine cellular process into a progressive condition that affects many systems in the body. Early diagnosis and consistent management are vital for improving quality of life.

Understanding MPS Types

Mucopolysaccharidoses (MPS) is not a single disorder but a group of related genetic conditions which is caused by the deficiency of a specific enzyme responsible for breaking down glycosaminoglycans (GAGs). While all types share similar underlying mechanisms and some overlapping symptoms, they differ in severity, progression, and the organs they primarily affect.

MPS I (Hurler, Hurler-Scheie, and Scheie Syndromes)

MPS I is caused by a deficiency of the enzyme alpha-L-iduronidase, and this type can range from mild to severe. Symptoms may include slow growth, stiff joints, distinctive facial features, breathing difficulties, and heart problems. The three subtypes represent a spectrum of severity, where Hurler is the most severe and Scheie the mildest.

MPS II (Hunter Syndrome)

Hunter Syndrome, also known as Hunter Syndrome, this form is X-linked, meaning it primarily affects boys. It occurs due to a shortage of the enzyme iduronate-2-sulfatase. Common symptoms include developmental delays, enlarged organs (like the liver and spleen), joint stiffness, and coarse facial features.

MPS III (Sanfilippo Syndrome)

MPS III mainly affects the brain and nervous system more than other organs. Caused by a deficiency in one of four enzymes needed to break down heparan sulfate, it often leads to behavioural issues, sleep disturbances, and gradual loss of cognitive skills over time.

MPS IV (Morquio Syndrome)

This type primarily affects bone and skeletal development. Children with MPS IV may have short stature, abnormally shaped bones, loose joints, and spinal problems, but their intelligence is typically not affected.

MPS VI (Maroteaux-Lamy Syndrome)

Caused by a lack of the enzyme arylsulfatase B, this type often leads to stiff joints, heart and lung complications, vision problems, and changes in facial appearance. Growth may also be affected, though intelligence usually remains normal.

MPS VII (Sly Syndrome)

One of the rarest forms of MPS, Sly Syndrome, results from a deficiency in the enzyme beta-glucuronidase. Symptoms can include enlarged organs, skeletal abnormalities, developmental delays, and breathing difficulties.

MPS IX (Natowicz Syndrome)

An extremely rare form caused by a deficiency of the enzyme hyaluronidase. It is often associated with soft tissue swelling, joint pain, and cyst-like growths, but tends to have milder symptoms compared to other MPS types.

Each type of MPS affects individuals differently, even among patients with the same diagnosis. Understanding these distinctions helps doctors concoct care plans and interventions that best support the person’s unique needs and quality of life.

Mucopolysaccharidoses Symptoms

The symptoms of mucopolysaccharidoses (MPS) can vary greatly from person to person, depending on the type of MPS, the specific enzyme deficiency, and how much of that enzyme activity remains. While all forms share a common underlying cause, the buildup of glycosaminoglycans (GAGs), the organs affected, and the rate of progression differ among types.

Common Symptoms Across Most MPS Types

Certain features tend to appear in many forms of MPS, especially during early childhood. These include:

• Distinct facial characteristics, such as a broad nose, thick lips, or an enlarged tongue
• Slow growth or short stature
• Stiff joints and reduced mobility
• Enlarged liver and spleen (organomegaly)
• Recurrent ear, nose, or throat infections
• Cloudy corneas or other vision problems
• Heart valve abnormalities
• Respiratory difficulties, often due to narrowed airways

These symptoms typically appear gradually, becoming more noticeable as the child grows.

Why Early Recognition Matters

Because MPS symptoms often resemble those of other, more common childhood conditions, diagnosis can be delayed. Recognising early warning signs and seeking genetic screening or enzyme testing can lead to timely intervention, improving both quality of life and treatment outcomes.

The Genetic Roots of MPS 

Mucopolysaccharidoses are genetic disorders that develop due to mutations in the genes responsible for producing enzymes that break down glycosaminoglycans (GAGs), complex sugars essential for building and maintaining connective tissues.

When these genes are altered, the body either produces defective enzymes or fails to produce them at all. As a result, GAGs gradually accumulate inside cells, leading to the progressive symptoms seen in MPS.

In most cases, MPS is inherited in an autosomal recessive pattern, meaning a child must receive one faulty gene from each parent to develop the condition. Parents who carry only one mutated gene typically show no symptoms but can pass it on to their children.

An exception is MPS II (Hunter Syndrome), which follows an X-linked recessive inheritance pattern. Since males have only one X chromosome, they are more likely to be affected, while females generally act as carriers without showing significant symptoms.

Diagnosis 

Diagnosing an MPS disorder involves a combination of medical history, physical examination, and laboratory testing. Doctors may suspect MPS if a child shows developmental delays, unusual physical traits, or skeletal abnormalities.

Common diagnostic tests include:

• Urine tests to detect excess glycosaminoglycans
• Blood enzyme assays to identify missing or defective enzymes
• Genetic testing to confirm the specific mutation and MPS type
• Imaging tests like X-rays or MRIs to assess bone and organ involvement

Mucopolysaccharidosis Treatment Options

While there is currently no permanent cure, medical advances have made it possible to manage symptoms, slow progression, and improve quality of life. Treatment depends on the MPS type and how much the disease has advanced.

1. Enzyme Replacement Therapy (ERT)

One of the most effective mucopolysaccharidosis treatment methods, ERT, involves injecting synthetic enzymes to replace the missing ones in the body. This helps reduce GAG buildup and improves mobility, breathing, and organ function in some MPS disorder types.

2. Hematopoietic Stem Cell Transplant (HSCT)

Also known as a bone marrow transplant, HSCT aims to introduce healthy donor cells capable of producing the missing enzyme. It’s most beneficial when done early, especially in severe forms like MPS I.

3. Gene Therapy (Emerging Treatment)

Research into gene therapy is promising, aiming to correct the genetic mutation responsible. Although still under study, it offers hope for a long-term solution in the future.

4. Supportive and Symptomatic Care

Managing mucopolysaccharidoses symptoms also involves physical therapy, surgery for skeletal or heart issues, vision correction, and speech or occupational therapy to improve daily living.

Conclusion

Caring for someone with a rare condition like MPS goes far beyond medical appointments. It’s a continuous journey of patience, planning, and emotional resilience. Families often find themselves guiding complex treatments, regular therapies, and lifelong care routines that can be both financially and emotionally demanding.

Comprehensive health coverage is equally vital in managing medical costs and ensuring continued access to expert care. Many families today live apart, with loved ones working or settling overseas while their parents or children remain in India. In such cases, ensuring consistent medical care and financial protection back home becomes even more important.

That’s where reliable health coverage makes all the difference. If you’re an Indian living abroad, Niva Bupa’s Health Insurance plan for NRIs offers a dependable way to protect your family’s health back home. It ensures that even when you’re miles away, your loved ones have access to quality healthcare and timely support, because peace of mind knows no borders. When it comes to caring for loved ones, financial peace of mind matters as much as the treatment itself.

FAQs

1. What causes MPS disease?

MPS disease is caused by inherited gene mutations that lead to enzyme deficiencies. These enzymes normally help break down complex sugars in the body, and their absence causes harmful buildup in tissues and organs.

2. What are the early mucopolysaccharidoses symptoms?

Early signs include slowed growth, stiff joints, frequent infections, and distinctive facial features. Some children may also show learning difficulties or behavioural changes depending on the MPS type.

3. Is MPS disease treatable?

While there’s no complete cure yet, modern mucopolysaccharidosis treatment options like enzyme replacement therapy and stem cell transplants can manage symptoms and slow disease progression.

4. How are different MPS types diagnosed?

Doctors use urine, blood, and genetic tests to identify which enzyme is missing. This helps confirm the MPS type and plan the most effective treatment.

5. Can genetic testing help prevent MPS disorder?

Yes. If a family has a history of MPS disorder, genetic counselling and prenatal testing can determine the risk for future children and support informed family planning decisions.